Key result
Liver cirrhosis is linked to ~15% lower circulating GLP-1 levels versus healthy controls.
Why the study?
The role of incretin hormones in the pathogenesis of liver cirrhosis is not clearly defined.
Are circulating levels of GLP-1 altered in patients with liver cirrhosis compared to healthy controls?
Cross-Sectional (n=80)
Are circulating levels of GLP-1 altered in patients with liver cirrhosis compared to healthy controls?
Circulating GLP-1 levels are significantly lower in patients with liver cirrhosis compared to healthy controls.
Answers are grounded in this paper and cite their sources.
Lower GLP-1 levels were associated with cirrhosis; this cross-sectional finding is hypothesis-generating and leaves open causal or therapeutic implications.
Background Glucagon-like peptide-1 (GLP-1), a gut-derived incretin hormone, plays a pivotal role in glucose-induced insulin secretion. Currently, the role of incretin hormones in the pathogenesis of cirrhosis is not clearly defined. This study aimed to investigate circulating levels of GLP-1 in liver cirrhosis and its association with the severity of liver disease.Methods A total of 80 participants including 39 patients with a definite diagnosis of liver cirrhosis and 41 healthy controls recruited in this cross-sectional study. Circulating levels of GLP-1 were determined using the ELISA method. The severity of liver cirrhosis was assessed according to the Child-Pugh, MELD (i), MELD-Na, MELD New, and UK end-stage liver disease score (UKELD) criteria.Results The mean age of patients and healthy subjects was 42.51 ± 12.80 and 42.07 ± 10.92 years, respectively (p value = .869). The mean MELD (i), MELD-Na, MELD New, UKELD, and Child-Pugh scores were 14.36 ± 4.26, 15.26 ± 4.81, 14.74 ± 4.66, 52.33 ± 3.82, and 7.28 ± 1.50, respectively. In this study, circulating levels of GLP-1 were statistically lower in cirrhotic patients compared with healthy controls (95.26 ± 17.15 vs 111.84 ± 38.14 pg/mL; p value = .017).Conclusion Larger prospective studies are needed to explore the incretin effect in cirrhosis patients compared with healthy individuals.
No takes yet. Share an insight, caveat, or question.
Nouri‐Vaskeh et al. (2020) conducted a cross-sectional in Liver cirrhosis (n=80). Liver cirrhosis vs. Healthy controls was evaluated on Circulating levels of GLP-1 (pg/mL) (p=.017). Circulating levels of GLP-1 were significantly lower in patients with liver cirrhosis compared with healthy controls (95.26 vs 111.84 pg/mL; P=0.017).
Synapse has enriched 10 related papers. Consider them for comparative context: